Launch of CSD500 in the Netherlands and Belgium

RNS Number : 8677T

Futura Medical PLC

09 October 2014

 



Strictly embargoed until 10am BST

9 October 2014

Futura Medical plc

("Futura" or the "Company")

Launch of CSD500 in the Netherlands and Belgium

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that its novel condom CSD500 is being launched today in the Netherlands and Belgium under Futura's brand Blue Diamond™.

The launch of CSD500 in these two countries is in line with Futura's strategy of licensing the product on a territorial basis to create a strong global distribution platform of companies, using either their own condom brand or our Blue Diamond™ brand.

The Blue Diamond™ condom is being unveiled this morning at a press conference beginning at 11am CET in Hilversum, Netherlands, hosted by Futura's Benelux distribution partner, Bizzy Diamond BV, and featuring Goedele Liekens, the renowned sex therapist and TV personality. Bizzy Diamond, a Dutch condom distributor founded in 2003, will market Blue Diamond™ online using a social media campaign to generate awareness of the brand.

Futura has this morning launched a dedicated website for the product, www.bluediamondcondom.com, along with .nl and .be e-commerce sites to be used by Bizzy Diamond for customers in the Netherlands and Belgium.

CSD500 contains Futura's erectogenic gel Zanifil® and benefits from three marketing claims, which have been clinically proven and approved by EU regulatory authorities: the maintenance of a firmer erection, maximised penile size and a longer lasting sexual experience for women.

James Barder, Futura's Chief Executive, said: "We are delighted that CSD500 is being launched this morning in the Netherlands and Belgium by our distribution partner. The product is being marketed under Futura's Blue Diamond™ brand and will be available online from a dedicated website serving these countries. We believe that the potential for online marketing of CSD500 is significant and we will gain valuable insights from this initial launch to inform the future rollout of the product."

For further information:

Futura Medical plc	+ 44 (0) 1483 685 670
James Barder, Chief Executive Officer
Mail to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)	+ 44 (0) 20 7496 3000
Aubrey Powell - Corporate Finance Brough Ransom - Sales
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare.  The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.  Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

MSCVKLBBZBFBFBB